Effects of Low Density Lipoprotein Apheresis on Clinical Markers of Peripheral Arterial Disease in the Patients undergoing HemodialYsis
|
Accession number;06A0784854
|
| Title;Effects of Low Density Lipoprotein Apheresis on Clinical Markers of Peripheral Arterial Disease in the Patients undergoing HemodialYsis |
| Author;
TSURUMI YUKO
(Yokohama City Univ., JPN)
TAMURA KOICHI
(Yokohama City Univ., JPN)
SAKAI MASASHI
(Yokohama City Univ., JPN)
AZUMA KOICHI
(Yokohama City Univ., JPN)
OZAWA MOTOKO
(Yokohama City Univ., JPN)
IWATSUBO KOSAKU
(Yokohama City Univ., JPN)
NAKAZAWA ICHIRO
(Yokohama City Univ., JPN)
YABANA MACHIKO
(Yokohama City Univ., JPN)
HIRAWA NOBUHITO
(Yokohama City Univ., JPN)
KIHARA MINORU
(Yokohama City Univ., JPN)
TOYA YOSHIYUKI
(Yokohama City Univ., JPN)
UMEMURA SATOSHI
(Yokohama City Univ., JPN)
|
Journal Title;Ther Res
|
Journal Code:Y0681A
|
ISSN:0289-8020
|
|
VOL.27;NO.9;PAGE.1745-1750(2006)
|
| Figure&Table&Reference;TBL.6, REF.9 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Objectives: The purpose of this study was to investigate the clinical effects of low density lipoprotein (LDL) apheresis for the treatment of peripheral arterial disease (PAD) in the patients undergoing hemodialysis. Methods: Eleven patients suffering from PAD were treated with ten sessions of LDL apheresis. The absolute walking distance, ankle brachial blood pressure index (ABI), and serum levels of lipids and chemokines were assessed at baseline, at the tenth session, and three months after the end of the treatment. Results: The absolute walking distance and ABI significantly improved after ten sessions of apheresis and the walking distance remained to be longer even at three months after the end of the treatment. Subsequently, patients were assigned to two groups according to the change of ABI at three months after the end of the treatment; patients with improved ABI (ABI responders, n=7), patients with worsened ABI (ABI non-responders, n=4). The absolute walking distance also tended to increase in the ABI responders at three months after the end of the treatment, but did not increase in the ABI non-responders. Even at the tenth session of LDL apheresis, the serum levels of oxidized LDL significantly decreased, and malondialdehyde-modified (MDA)-LDL and fibrinogen also remained to be lower in the ABI responders. Conclusion: These results suggest that LDL apheresis not only decreases serum levels of lipids, but also inhibits the inflammation and oxidized stress in the patients suffering from PAD and undergoing hemodialysis. (author abst.) |
|
|
|
Related Articles;
|
|
